Title : A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).

Pub. Date : 2016

PMID : 27229742






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODS: Subjects were mCRC patients with mutated KRAS who showed disease aggravation even after two regimens with oxaliplatin and irinotecan. Oxaliplatin KRAS proto-oncogene, GTPase Homo sapiens